Table 1 HCC cell lines and their correlations with tumors.
Cell Line | Correlation (P value) | Sex | Ethnicity/Race | Age | Known cancer etiology or other characteristics |
|---|---|---|---|---|---|
HepG2 | 0.55 (3.4E-4) | M | Caucasian/NA | 15 | No evidence of a Hepatitis B virus genome |
C3A | 0.53 (1.1E-3) | M | Caucasian/NA | 15 | No evidence of a Hepatitis B virus genome; derivative of HepG2 |
huH-1 | 0.52 (1.9E-3) | M | Asian/Japanese | 53 | HBs-antigen carrier |
JHH-5 | 0.51 (3.3E-3) | M | Asian/Japanese | 50 | Small liver cancer observed in the chronic hepatitis; integration of the HBV-DNA was not observed |
SNU-878 | 0.51 (3.3E-3) | F | Asian/Korean | 54 | One of newer cell lines in the SNU series |
SNU-761 | 0.5 (5.5E-3) | M | Asian/Korean | 49 | One of newer cell lines in the SNU series |
HuH-7 | 0.49 (8.8E-3) | M | Asian/Japanese | 57 | Well differentiated hepatocellular carcinoma |
SNU-886 | 0.48 (1.4E-2) | M | Asian/Korean | 57 | One of newer cell lines in the SNU series |
JHH-7 | 0.47 (2.1E-2) | M | Asian/Japanese | 53 | HBs-Ag positive hepatocellular carcinoma with liver cirrhosis |
PLC/PRF/5 | 0.47 (2.1E-2) | M | NA | 24 | Malignant liver cancer with HBsAg positive |
Alexander cells | 0.46 (3.1E-2) | M | NA | 24 | Malignant liver cancer with HBsAg positive |
Hep 3B2.1-7 | 0.46 (3.1E-2) | M | Black/NA | 8 | Hepatitis B virus DNA was detected |
Li-7 | 0.46 (3.1E-2) | NA | NA | NA | NA |
JHH-2 | 0.45 (4.5E-2) | M | Asian/Japanese | 57 | Integration of the HBV-DNA was not observed |
SNU-387 | 0.44 (0.06) | F | Asian/Korean | 41 | Patient treated by transcatheter arterial embolization with lipoidol plus a combination of doxorubicin and mitomycin-C |
SNU-475 | 0.42 (0.12) | M | Asian/Korean | 43 | Taken from a patient prior to cytotoxic therapy |
JHH-4 | 0.42 (0.12) | M | Asian/Japanese | 51 | HBs antigen-negative; HCV was not detected |
JHH-1 | 0.41 (0.16) | M | Asian/Japanese | 50 | Complication of hepatic cirrhosis and hepatocellular carcinoma |
SNU-449 | 0.41 (0.16) | M | Asian/Korean | 52 | Hepatitis B virus DNA was detected; taken from a patient prior to cytotoxic therapy |
JHH-6 | 0.39 (0.25) | F | Asian/Japanese | 57 | HBV-DNA was not integrated; undifferentiated hepatocellular carcinoma |
SNU-423 | 0.36 (0.44) | M | Asian/Korean | 40 | Hepatitis B virus DNA was detected; treated by transcatheter arterial embolization with lipoidol plus doxorubicin |
SNU-182 | 0.35 (0.51) | M | Asian/Korean | 24 | Taken from a patient prior to cytotoxic therapy |
HLF | 0.33 (0.64) | M | NA | 68 | Hepatoma, non-differentiated |
HLE | 0.32 (0.70) | M | NA | 68 | Hepatoma, non-differentiated |
SNU-398 | 0.28 (0.89) | M | Asian/Korean | 42 | Hepatitis B virus (HBV) DNA was detected; treated by transcatheter arterial embolization with lipoidol plus a combination of doxorubicin and mitomycin-C |